Vol. 2 No. 5 (2008) | Hematology Meeting Reports

Current Issue

Vol. 2 No. 5 (2008)

23 June 2009

View this Issue

Vol. 2 No. 5 (2008)

Published: 23 June 2009

New Drugs in Hematology, Bologna, Italy 5-7 October 2008

Abstracts

Myelodysplastic syndromes

M Cazzola

https://doi.org/10.4081/hmr.v2i5.717

275

PDF: 164
- PDF
Organ damage and iron overload

E Angelucci, C Cogoni, M Pettinau, F Pilo, C Targhetta, F Zacchedu

https://doi.org/10.4081/hmr.v2i5.718

368

PDF: 1482
- PDF
Progress in the management of iron overload in erytrocyte disorders

MD Cappellini, E Cassinerio, L Zanaboni, G Fabio, P Pattoneri

https://doi.org/10.4081/hmr.v2i5.719

323

PDF: 1797
- PDF
Ph positive-leukemias

F Guilhot, L Roy, J Guilhot, PJ Saulnier, JM Gombert, A Turhan

https://doi.org/10.4081/hmr.v2i5.720

251

PDF: 230
- PDF
Thyrosin kinase inhibitors: nilotinib

F Castagnetti, F Palandri, G Gugliotta, A Poerio, M Amabile, S Soverini, G Martinelli, M Baccarani, G Rosti

https://doi.org/10.4081/hmr.v2i5.721

452

PDF: 512
- PDF
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib

G Martinelli, I Iacobucci, D Cilloni, P Giannoulia, S Soverini, PP Piccaluga, C Papayannidis, S Paolini, C Terragna

https://doi.org/10.4081/hmr.v2i5.722

295

PDF: 334
- PDF
Peripheral T-cell lymphomas

SA Pileri, C Agostinelli, C Campidelli, F Bacci, E Sabattini, A Pileri Jr, PP Piccaluga

https://doi.org/10.4081/hmr.v2i5.723

335

PDF: 849
- PDF
Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i5.724

358

PDF: 2639
- PDF
A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang

https://doi.org/10.4081/hmr.v2i5.725

272

PDF: 258
- PDF
Chronic lymphocytic leukemia

F Caligaris-Cappio

https://doi.org/10.4081/hmr.v2i5.727

274

PDF: 2656
- PDF
Monoclonal antibodies (update): CD20, rituximab

C Hagenbeek

https://doi.org/10.4081/hmr.v2i5.728

275

PDF: 191
- PDF
90Y-ibritumumab tiuxetan (Zevalin)

PL Zinzani

https://doi.org/10.4081/hmr.v2i5.729

308

PDF: 459
- PDF
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia

C Dearden

https://doi.org/10.4081/hmr.v2i5.731

266

PDF: 297
- PDF
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma

P Martin, D Goldenberg, JP Leonard

https://doi.org/10.4081/hmr.v2i5.732

235

PDF: 436
- PDF
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin

S Amadori

https://doi.org/10.4081/hmr.v2i5.733

246

PDF: 631
- PDF
Update on galiximab: anti-CD80 monoclonal antibody

MS Czuczman

https://doi.org/10.4081/hmr.v2i5.734

317

PDF: 351
- PDF
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin

JF DiJoseph, K Khandke, MM Dougher, DY Evans, DC Armellino, PR Hamann, NK Damle

https://doi.org/10.4081/hmr.v2i5.735

784

PDF: 2610
- PDF
Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma

C Assaf

https://doi.org/10.4081/hmr.v2i5.736

369

PDF: 405
- PDF
Monoclonal antibodies (novel): humax-CD20, ofatumumab

A Hagenbeek

https://doi.org/10.4081/hmr.v2i5.737

277

PDF: 282
- PDF
Lumiliximab in chronic lymphocytic leukemia

TS Lin

https://doi.org/10.4081/hmr.v2i5.738

314

PDF: 521
- PDF
Bevacizumab as an anti-VEGF strategy in lymphoma

SJ Horning

https://doi.org/10.4081/hmr.v2i5.739

424

PDF: 250
- PDF
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams

BD Cheson

https://doi.org/10.4081/hmr.v2i5.741

290

PDF: 368
- PDF
Aurora kinase inhibitor: AS703569

A Gianella-Borradori

https://doi.org/10.4081/hmr.v2i5.742

318

PDF: 358
- PDF
From cell biology to therapy: lenalidomide in untreated multiple myeloma

A Palumbo, P Falco, F Gay, V Magarotto, F Patriarca, C Nozzoli, M Boccadoro

https://doi.org/10.4081/hmr.v2i5.744

264

PDF: 300
- PDF
HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells

PWHI Parren

https://doi.org/10.4081/hmr.v2i5.740

552

PDF: 681
- PDF
Pha-739358: a pan-aurora kinase inhibitor

R Paquette, N Shah, C Sawyers, G Martinelli, J Nicoll, M Chalukya

https://doi.org/10.4081/hmr.v2i5.743

330

Untitled: 0

PDF: 495
- PDF
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma

P Richardson, T Hideshima, C Mitsiades, R Schlossman, J Laubach, I Ghobrial, N Raje, N Munshi, K Anderson

https://doi.org/10.4081/hmr.v2i5.745

254

PDF: 388
- PDF
Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas

A Dreyling

https://doi.org/10.4081/hmr.v2i5.749

438

PDF: 504
- PDF
From cell biology to therapy: forodesine

M Duvic

https://doi.org/10.4081/hmr.v2i5.746

476

PDF: 911
- PDF
Flavopiridol (alvocidib) in chronic lymphocytic leukemia

TS Lin, B Fischer, KA Blum, M Brooker-McEldowney, ME Moran, LA Andritsos, JM Flynn, MA Phelps, JT Dalton

https://doi.org/10.4081/hmr.v2i5.747

420

PDF: 894
- PDF
mTOR inhibitors for the treatment of lymphoma

TE Witzig

https://doi.org/10.4081/hmr.v2i5.748

287

PDF: 394
- PDF
Multiple myeloma

J San Miguel

https://doi.org/10.4081/hmr.v2i5.750

210

PDF: 147
- PDF
Proteasome inhibitors: bortezomib in multiple myeloma

M Cavo, MC Pallotti, L Pantani, A Petrucci, A Brioli, C Terragna, N Testoni, G Marzocchi, S Durante, M Ceccolini, G Perrone, P Tacchetti, E Zamagni, P Tosi, M Baccarani

https://doi.org/10.4081/hmr.v2i5.751

245

PDF: 279
- PDF
Bortezomib in lymphomas

A Goy

https://doi.org/10.4081/hmr.v2i5.752

252

PDF: 232
- PDF
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma

P Richardson, C Mitsiades, J Laubach, C Conant, T Hideshima, D Chauhan, R Schlossman, I Ghobrial, N Munshi, KC Anderson

https://doi.org/10.4081/hmr.v2i5.753

483

PDF: 317
- PDF
Novel proteasome inhibitors

P Tosi, MC Pallotti, L Pantani, A Petrucci

https://doi.org/10.4081/hmr.v2i5.754

259

PDF: 414
- PDF
Decitabine in myeloid malignancies

HI Saba

https://doi.org/10.4081/hmr.v2i5.755

240

PDF: 924
- PDF
J-L. Harousseau Tipifarnib in hematologic malignancies

JL Harousseau

https://doi.org/10.4081/hmr.v2i5.756

243

PDF: 329
- PDF
Is there a role for immunotherapy in Hodgkin’s disease?

B Böll, A Engert

https://doi.org/10.4081/hmr.v2i5.757

225

PDF: 628
- PDF
New agents for the treatment of acute myeloid leukemia: midostaurin

S Amadori

https://doi.org/10.4081/hmr.v2i5.760

279

PDF: 955
- PDF
Lestaurtinib as a FLT3 inhibitor

AK Burnett

https://doi.org/10.4081/hmr.v2i5.761

247

PDF: 231

Untitled: 0
- PDF

© PAGEPress 2008-2026 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.